Unlike the aberrant expression of CDK-1 in stage-2 colon and rectum adenocarcinoma being associated with a higher risk of metastasis [75], mutations in the catalytic subunit of CDK-4 gene has also been reported to be common and its abnormal expression has been uncovered in over 90 % of all bowel cancers [76]. The gene discussed is CDK1; the disease is intestinal cancer.